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BACKGROUND The evidence for the use of conventional percutaneous coronary
intervention (cPCI), manual thrombectomy (MT) and mechanical thrombectomy
(McT) during primary PCI (PPCI) for ST-segment elevation myocardial infarction
(STEMI) is conﬂicting. Moreover, there is a dearth of direct evidence comparing MT
versus McT. A network meta-analysis allows for indirect comparisons in a head-to-
head fashion.
METHODS Electronic search of PubMed, EBSCO, Google Scholar and abstracts from
conferences identiﬁed 41 randomized trials (Fig 1A) that compared the use of at least 2
of the 3 strategies (cPCI, MT, and McT) during PPCI. Mixed treatment analysis was
performed for the earliest available (1-36 months) clinical and procedural endpoints.
RESULTS When compared with cPCI, MT and McT were associated with a lower
incidence of major adverse cardiovascular events (MACE), which is a composite of
death, myocardial infarction (MI) and target vessel revascularization (TVR)(Fig 1B).
The rate of complete ST-segment resolution (> 50-70%) at 60 minutes (STR) and post-
procedural myocardial blush grade  2 (MBG) were higher with MT and McT (Fig 1B).
Additionally, MT was associated with a lower incidence of MI and higher ﬁnal ejection
fraction (EF) compared to cPCI (Figs 1B and 1C). However, MT was no different than
McT for all the endpoints. No statistical inconsistency was noted in the network. MT
was highest in hierarchical ranking order (highest to lowest) by comparative efﬁcacy
for death, MI, stent thrombosis, MBG, EF (up to 3 months) and ﬁnal infarct size (up to
3 months) while McT was highest for MACE, TVR and STR (Fig 1D). cPCI was lowest in
the hierarchical ranking order for all endpoints.
CONCLUSION Reducing the thrombus burden during PPCI for STEMI with either MT
or McT improves clinical outcomes and procedural efﬁcacy compared to cPCI.CORONARY: CARDIOVASCULAR PHARMACOLOGY
CRT-136
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OHBACKGROUND Choosing the right anti-coagulant (AC) during percutaneous coronary
intervention (PCI) for the right patient that balances the bleeding risk with ischemic
efﬁcacy is an ongoing challenge. We did a network meta-analysis to compare the
currently used ACs for PCI.
METHODS We searched PubMed, The Cochrane Library, and relevant meeting ab-
stracts for randomized trials that compared unfractionated heparin (UFH), bivalir-
udin, and low molecular weight heparin (LMWH) with or without glycoprotein IIb/IIIa
inhibitor (GPI) for PCI. Endpoints (up to 30-day) included were: major bleeding (MB),
death, major adverse cardiac events (MACE), and stent thrombosis (ST).
RESULTS We analyzed 74 trials (n ¼ 73,760) allocated to 6 AC combinations
(Figure 1A). Compared to UFH, UFHþGPI, bivalirudin, LMWH, and LMWHþGPI were
associated with lower MACE (Figure 1B). The hierarchy for MACE (highest to lowest)
was LMWHþGPI, UFHþGPI, bivalirudinþGPI, LMWH, Bivalirudin and UFH. While
there was no statistical difference between ACs for death, LMWH was ranked the
highest and UFH the lowest (SUCRA values 72% and 28% respectively). Bivalirudin
was the safest AC (Figure 1C and 1D), and was associated with lower MB compared to
UFHþGPI (odds ratio (OR) 0.54, 95% conﬁdence interval (CI) 0.42-0.68) and UFH (OR
0.68, CI 0.51-0.90). However, ST was higher with bivalirudin compared to UFHþGPI
(OR 1.72, CI 1.10-2.67).
CONCLUSIONS LMWHþGPI and UFHþGPI are the most effective and bivalirudin the
safest AC for PCI. AC selection maybe tailored to patient’s risk proﬁle.CORONARY: COMPLEX CORONARY INTERVENTION
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BACKGROUND The clinical beneﬁts of paxlitaxel-coated balloon angioplasty (PCB)
have been extensively studied in bare metal stent in-stent restenosis (BMS-ISR) and
in drug eluting stent in-stent restenosis (DES-ISR). The GARO Registry is a dedicated
‘all comers’ study in an unselected patient population with DES-ISR to elucidate the
clinical beneﬁts of PCB angioplasty for various types of DES-ISR in a routine clinical
setting.
METHODS Under the supervision of the GARO (Groupe Angioplastie de la Région
Ouest) all data for patients treated by the PCB based on the Paccocath Technology
(SeQuent Please, B.Braun Melsungen AG) for In DES-ISR were collected in a pro-
spective data base. Quantitative analyses of the angiography of the procedure were
made by an independent core lab. The primary endpoint was clinically driven TLR at
9 months while secondary endpoints consisted of the clinically driven rates of MACE,
MI and cardiac death.
RESULTS A total of 206 patients (67.7  10.3 y, 80.6% male gender) with 210 DES-ISR
lesions were recruited in 15 French study centers. Major cardiovascular risk factors
